Copyright Reports & Markets. All rights reserved.

Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Report 2018

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Chronic Idiopathic Constipation (CIC) Drugs Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 Lubiprostone Market Performance (Volume)
      • 2.1.2 Linaclotide Market Performance (Volume)
      • 2.1.3 Others Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 Lubiprostone Market Performance (Value)
      • 2.1.2 Linaclotide Market Performance (Value)
      • 2.1.3 Others Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospitals & Clinics Market Performance (Volume)
      • 3.1.2 Ambulatory Surgical Centres Market Performance (Volume)
      • 3.1.3 Long Term Care Centres Market Performance (Volume)
      • 3.1.4 Others Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Actavis
      • 4.1.1 Actavis Profiles
      • 4.1.2 Actavis Product Information
      • 4.1.3 Actavis Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.1.4 Actavis Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.2 Chugai Pharmaceutical
      • 4.2.1 Chugai Pharmaceutical Profiles
      • 4.2.2 Chugai Pharmaceutical Product Information
      • 4.2.3 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.2.4 Chugai Pharmaceutical Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.3 Ferring International Center S.A.
      • 4.3.1 Ferring International Center S.A. Profiles
      • 4.3.2 Ferring International Center S.A. Product Information
      • 4.3.3 Ferring International Center S.A. Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.3.4 Ferring International Center S.A. Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.4 Synergy Pharmaceuticals
      • 4.4.1 Synergy Pharmaceuticals Profiles
      • 4.4.2 Synergy Pharmaceuticals Product Information
      • 4.4.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.4.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.5 Pfizer
      • 4.5.1 Pfizer Profiles
      • 4.5.2 Pfizer Product Information
      • 4.5.3 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.5.4 Pfizer Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.6 GlaxoSmithKline
      • 4.6.1 GlaxoSmithKline Profiles
      • 4.6.2 GlaxoSmithKline Product Information
      • 4.6.3 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.6.4 GlaxoSmithKline Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.7 Roche Holding AG
      • 4.7.1 Roche Holding AG Profiles
      • 4.7.2 Roche Holding AG Product Information
      • 4.7.3 Roche Holding AG Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.7.4 Roche Holding AG Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.8 Sanofi
      • 4.8.1 Sanofi Profiles
      • 4.8.2 Sanofi Product Information
      • 4.8.3 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.8.4 Sanofi Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.9 Bayer AG
      • 4.9.1 Bayer AG Profiles
      • 4.9.2 Bayer AG Product Information
      • 4.9.3 Bayer AG Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.9.4 Bayer AG Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.10 Salix Pharmaceuticals Ltd
      • 4.10.1 Salix Pharmaceuticals Ltd Profiles
      • 4.10.2 Salix Pharmaceuticals Ltd Product Information
      • 4.10.3 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation (CIC) Drugs Business Performance
      • 4.10.4 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation (CIC) Drugs Business Development and Market Status
    • 4.11 Sucampo Pharmaceuticals Inc
    • 4.12 Ironwood Pharmaceuticals
    • 4.13 Ferring International Center S.A.

    5 Market Performance for Manufacturers

    • 5.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 China Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 China Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 China Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 Japan Market Performance for Manufacturers
      • 6.2.1 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 Japan Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 Japan Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 Japan Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 South Korea Market Performance for Manufacturers
      • 6.3.1 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 South Korea Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 South Korea Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 South Korea Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Taiwan Market Performance for Manufacturers
      • 6.4.1 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 India Market Performance for Manufacturers
      • 6.5.1 India Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 India Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 India Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 India Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Southeast Asia Market Performance for Manufacturers
      • 6.6.1 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Australia Market Performance for Manufacturers
      • 6.7.1 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Australia Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Australia Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Australia Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Chronic Idiopathic Constipation (CIC) Drugs Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Performance (Sales Point)

    • 7.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) by Regions 2013-2018
    • 7.4 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 China Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 India Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospitals & Clinics Industry
    • 11.2 Ambulatory Surgical Centres Industry
    • 11.3 Long Term Care Centres Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 China Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 Japan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 South Korea Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Taiwan Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 India Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Southeast Asia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Australia Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.10 Chronic Idiopathic Constipation (CIC) Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 Lubiprostone Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 Linaclotide Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.4 Others Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospitals & Clinics Sales and and Growth Rate 2019-2024
      • 12.4.3 Ambulatory Surgical Centres Sales and and Growth Rate 2019-2024
      • 12.4.4 Long Term Care Centres Sales and and Growth Rate 2019-2024
      • 12.4.5 Others Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Chronic Idiopathic Constipation (CIC) Drugs for these regions, from 2012 to 2023 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

    Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs market competition by top manufacturers/players, with Chronic Idiopathic Constipation (CIC) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Actavis
    Chugai Pharmaceutical
    Ferring International Center S.A.
    Synergy Pharmaceuticals
    Pfizer
    GlaxoSmithKline
    Roche Holding AG
    Sanofi
    Bayer AG
    Salix Pharmaceuticals Ltd
    Sucampo Pharmaceuticals Inc
    Ironwood Pharmaceuticals
    Progenics Pharmaceuticals

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Lubiprostone
    Linaclotide
    Others

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Chronic Idiopathic Constipation (CIC) Drugs for each application, including
    Hospitals & Clinics
    Ambulatory Surgical Centres
    Long Term Care Centres
    Others

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now